NICE recommends oral treatment for preventing episodic migraine

The first oral treatment for the prevention of migraines has been recommended by the National Institute for Health and Care Excellence (NICE) in draft guidance.1Rimegepant (Vydura) is recommended for preventing episodic migraine in adults who have at least four and fewer than 15 migraine attacks a month, and where at least three preventative treatments have previously failed. Currently, preventative treatments used to treat migraine, which include erenumab, fremanezumab, and galcanezumab, are all injections. Rimegepant may be more acceptable to patients as it is taken as a wafer which dissolves under the tongue.Over 5.6 million people in England are thought to have episodic migraines with an estimated 190 000 migraine attacks experienced every day.Rimegepant, made by Pfizer, works by stopping the release of the protein calcitonin gene related peptide. This causes intense inflammation in the meninges which protects the brain and is responsible for the severe pain associated with migraine attacks.Clinical…
Read Original Article: NICE recommends oral treatment for preventing episodic migraine »